181 results on '"Moschini, Marco"'
Search Results
2. The effect of race/ethnicity on cancer-specific mortality after trimodal therapy
3. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer
4. Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023?
5. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non–muscle-invasive Bladder Cancer
6. Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical Outcomes
7. The Impact of Venous Thromboembolism on Upper Tract Urothelial Carcinomas Undergoing Open or Minimally Invasive Radical Nephroureterectomy in the USA: Perioperative Outcomes and Health Care Costs from Insurance Claims Data
8. Neoadjuvant Versus Adjuvant Chemotherapy in Non-Metastatic Locally-Advanced Stage Radical Cystectomy Candidates
9. Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non–muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics
10. Repeat Transurethral Resection for Non–muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era
11. NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring.
12. Re: Stamatio Katsimperis, Lazaros Tzelves, Zafer Tandogdu, et al. Complications After Radical Cystectomy: A Systematic Review and Meta-analysis of Randomized Controlled Trials with a Meta-regression Analysis. Eur Urol Focus 2023;9:920–9
13. PD02-05 THE IMPACT OF VENOUS THROMBOEMBOLISM ON MUSCLE INVASIVE BLADDER CANCER (MIBC) PATIENTS UNDERGOING OPEN OR MINIMALLY-INVASIVE RADICAL CYSTECTOMY IN THE UNITED STATES: PERIOPERATIVE OUTCOMES AND HEALTH-CARE COSTS FROM INSURANCE CLAIMS DATA
14. Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
15. PD02-06 COMPREHENSIVE GENOMIC PROFILING (CGP) OF CLINICAL T2-4N0M0 MUSCLE-INVASIVE BLADDER CANCER (MIBC) TREATED WITH NEOADJUVANT PEMBROLIZUMAB OR CISPLATIN-BASED CHEMOTHERAPY BEFORE RADICAL CYSTECTOMY (RC)
16. Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer
17. PD41-10 UROLOGICAL FOLLOW-UP OF LYNCH SYNDROME: UTUC INCIDENCE AND MUTATIONAL PATTERNS IN A DEDICATED OUTPATIENT CLINIC
18. MP77-11 NOMOGRAM PREDICTING OPTIMAL CANDIDATES FOR BLADDER-SPARING STRATEGIES AFTER NEOADJUVANT IMMUNOTHERAPY
19. PD45-05 WHEN DOES SYSTEMATIC BIOPSY INFORMATION MATTER THE MOST? IDENTIFYING INDEPENDENT PREDICTORS OF DISEASE DOWNGRADING AT RADICAL PROSTATECTOMY IN HIGH GRADE PROSTATE CANCER BASED ON A LARGE MULTI-INSTITUTIONAL SERIES
20. MP53-04 NEOADJUVANT VERSUS ADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER: A DECISION ANALYSIS
21. PD30-06 PHOTODYNAMIC DIAGNOSIS (PDD) DIRECTED BIOPSIES VS WHITE LIGHT BLADDER MAPPING IN PATIENTS WITH POSITIVE CYTOLOGY AND NEGATIVE PREOPERATIVE WORKUP: AN INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY
22. MP71-15 CANCER CONTROL RATES IN ADEQUATE VERSUS INADEQUATE TREATMENT WITH ADJUVANT IMMUNOTHERAPY INSTILLATIONS WITH BCG
23. PD34-10 FIRST RESULTS OF NURE-COMBO: a PHASE 2 STUDY OF NEOADJUVANT NIVOLUMAB (NIVO) AND NAB-PACLITAXEL (ABX) FOLLOWED BY POSTSURGICAL ADJUVANT NIVO IN PATIENTS (PTS) WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC)
24. MP71-07 THE IMPACT OF CENTRALIZED UROPATHOLOGY REVIEW IN THE MANAGEMENT OF BLADDER CANCER PATIENTS AT THE TIME OF TRANSURETHRAL RESECTION OF THE BLADDER
25. MP16-11 LONG-TERM OUTCOMES OF PTA HIGH GRADE INTERMEDIATE AND HIGH RISK BLADDER CANCER PATIENTS
26. MP53-18 IMPACT OF NEOADJUVANT CHEMO-IMMUNOTHERAPY ON INTRA AND POST OPERATIVE OUTCOMES IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY AND PELVIC LYMPH NODE DISSECTION: PROSPECTIVE SURGICAL ASSESSMENT FROM THE NURE-COMBO TRIAL
27. PD34-12 THE OPTIMAL NUMBER OF INDUCTION CHEMOTHERAPY CYCLES IN CLINICALLY LYMPH NODE-POSITIVE BLADDER CANCER
28. MP53-02 RISK OF NODE METASTASES IN MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMO- OR IMMUNOTHERAPY AND RADICAL CYSTECTOMY WITH BILATERAL PELVIC LYMPH NODE DISSECTION
29. Temporal trends and cancer-specific mortality in non-metastatic muscle-invasive urothelial carcinoma of the urinary bladder treated with trimodal therapy
30. MP08-11 IMPACT OF PRE-SURGERY EGFR AND HER2 PLASMA LEVELS ON POST-SURGICAL OUTCOMES IN BLADDER CANCER PATIENTS RECEIVING RADICAL CYSTECTOMY
31. PD38-03 DETECTION OF LYMPH NODE INVOLVEMENT BEFORE RADICAL CYSTECTOMY: DIAGNOSTIC PERFORMANCE OF 18F-FDG PET/CT AND IMPLICATIONS IN THE THERAPEUTIC MANAGEMENT
32. MP38-20 RISK OF UPPER URINARY TRACT DISSEMINATION IN cT3 BLADDER CANCER PATIENTS TREATED WITH DOUBLE-J STENT VERSUS NEPHROSTOMY TUBE PRIOR TO RADICAL CYSTECTOMY
33. PD30-01 DEFINING INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER: A COMPARATIVE STUDY OF EAU AND IBCG CRITERIA
34. Variation in Follow-Up after Radical Cystectomy for Bladder Cancer—An Inventory Roundtable and Literature Review
35. Peri- and post-operative outcomes of robot-assisted radical cystectomy after the implementation of the EAU guidelines recommendations for collecting and reporting complications at a high-volume referral center
36. Robotic-assisted radical cystectomy with cutaneous ureterostomies: a contemporary multicenter analysis
37. Adjuvant intravesical therapy in intermediate‐risk non‐muscle‐invasive bladder cancer
38. Use of 18F‐fluoro‐2‐deoxy‐d‐glucose (18F‐FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients
39. Optimizing the use of next-generation sequencing assays in patients with urothelial carcinoma: recommendations by the 2023 San Raffaele Retreat panel
40. WCN24-1072 ACUTE KIDNEY INJURY (AKI) AND ACUTE KIDNEY DISEASE AFTER RADICAL CYSTECTOMY FOR MUSCLE INVASIVE BLADDER CANCER: A NEW DISCOVER
41. Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations in Bladder Cancer
42. Non-Surgical Bladder-Sparing Multimodal Management in Organ-Confined Urothelial Carcinoma of the Urinary Bladder: A Population-Based Analysis
43. Trimodal therapy effect on survival in urothelial vs non‐urothelial bladder cancer
44. Long‐term functional outcomes after robot‐assisted radical cystectomy with intracorporeal ileal orthotopic neobladder
45. Addition of neoadjuvant chemotherapy to a ‘quadrifecta’ composite in radical cystectomy
46. The optimal number of induction chemotherapy cycles in clinically lymph node‐positive bladder cancer.
47. Global burden, risk factors, and temporal trends of ureteral cancer: a comprehensive analysis of cancer registries.
48. Perioperative Outcomes and Trends in Transurethral Resection of Bladder Tumors with Photodynamic Diagnosis: Results from the GeRmAn Nationwide Inpatient Data Study.
49. Application of the ERAS guidelines in pediatric urological surgery: a systematic review.
50. How can we reduce morbidity after robot‐assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.